Recipharm Invests in Isofol Medical - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Recipharm Invests in Isofol Medical


Recipharm and Isofol Medical AB, a Gothenburg, Sweden-based pharmaceutical company, announced the formation of a collaboration to strengthen the development program of Isofol’s lead drug candidate Modufolin.

At the same time, Recipharm Venture Fund, a life science sector investor, announced Aug. 26 that it invested $1.15 million (SEK 8 million) in Isofol Medical.

Isofol Medical AB is currently evaluating Modufolin in two clinical phase studies. Modufolin is an endogenous folate-based biomodulator, developed to increase the efficacy and decrease the side effects of chemotherapeutic agents used in the treatment of solid tumors.

“Given the promising clinical data we have obtained to date we want to secure the long term manufacture and supply of Modufolin for its future commercialization. With Recipharm’s investment of 8 MSEK in Isofol we have now raised 45 MSEK during the last 8 months,” Anders Rabbe, managing director of Isofol commented.

Source: Recipharm and Isofol Medical AB

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here